Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World July 28, 2014 Andy Extance	Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover.
Chemistry World November 24, 2014 Andy Extance	Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis.
Chemistry World July 30, 2013 Emma Stoye	Thousands face job cuts after Valeant's Bausch buyout Canadian pharmaceutical company Valeant plans to lay off up to 2700 staff to help finance its $8.7 billion acquisition of US eye health specialist Bausch & Lomb.
Chemistry World February 23, 2015 Phillip Broadwith	Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion
The Motley Fool September 12, 2008 Brian Lawler	A New Wrinkle for an Old Drug Allergan's muscle relaxant Botox performs well in two studies testing its ability to prevent migraine headaches.
BusinessWeek October 13, 2003 Arlene Weintraub	He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug?
The Motley Fool May 27, 2009 Brian Orelli	A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news.
CRM February 2003 David Myron	Support Gets a Face-Lift Allergan was able to automate the routing of 80 percent of all inbound, Web-generated emails, based on the business rules the company put in place.
The Motley Fool June 5, 2008 Brian Lawler	Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth.
Chemistry World June 10, 2008 James Mitchell Crow	A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker.
Chemistry World January 25, 2013 Andrew Turley	Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million
The Motley Fool November 22, 2006 Brian Lawler	Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news.
The Motley Fool May 6, 2009 Robert Steyer	Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags.
Chemistry World July 29, 2015 Katrina Megget	Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell.
CIO December 14, 2010 Kim S. Nash	How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan.
The Motley Fool September 20, 2007 Brian Lawler	Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note.
Chemistry World June 24, 2015 Matthew Gunther	Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal.
The Motley Fool January 31, 2007 Brian Lawler	No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now.
The Motley Fool October 7, 2009 Jim Mueller	Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble.
The Motley Fool December 16, 2005 Stephen D. Simpson	A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note.
The Motley Fool December 29, 2008 Brian Orelli	Thicker Lashes, Fatter Wallets The Food and Drug Administration approves Allergan's Latisse, a treatment for sparse eyelashes.
The Motley Fool December 15, 2003 Alyce Lomax	No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market.
BusinessWeek December 25, 2006 Palmeri & Weintraub	Silicone Goes Subtle Allergan's campaign relies on friendly persuasion.
The Motley Fool December 7, 2006 Dan Caplinger	Don't Swallow the Poison Pill Corporate takeovers are often profitable for investors, so why stop them?
The Motley Fool March 12, 2009 Robert Steyer	A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another.
The Motley Fool November 9, 2004 Dave Marino-Nachison	Moguls Match Up Over News Corp. Shares of international media giant News Corp. fell nearly 4% yesterday following the company's announcement that it adopted a "shareholder rights plan," better known as a "poison pill".
Chemistry World March 25, 2015 Phillip Broadwith	Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals.
The Motley Fool April 11, 2011 Jim Mueller	A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too.
The Motley Fool February 9, 2006 Stephen D. Simpson	Alcon Makes Traders Cry Disappointing guidance lets some of the air out of the valuation, but not enough.
The Motley Fool April 6, 2011 Brian Orelli	Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire.
Chemistry World September 6, 2012 Andrew Turley	Valeant buys $2.6bn skincare firm Canadian pharma company Valeant is to buy US firm Medicis in a $2.6 billion deal. Medicis produces prescription dermatology products as well as over the counter products.
The Motley Fool March 30, 2011 Brian Orelli	Valeant Vultures Will Cephalon manage to rebuff Valeant's advances?
The Motley Fool December 2, 2010 Brian Orelli	A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying.
The Motley Fool January 15, 2009 Robert Steyer	Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy.
Chemistry World November 27, 2015 Anthony King	Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes.